Search

Your search keyword '"Kurth J"' showing total 321 results
Start Over Author "Kurth J"
321 results on '"Kurth J"'

1. Analysis of Literacy Content in IEPs of Students With Complex Support Needs.

Author

Zagona, Alison L., Lansey, K. R., Kurth, J. A., Loyless, R., and Stevens, Elizabeth A.

Subjects
INDIVIDUALIZED education programs, EMERGENT literacy, GENERAL education, ACADEMIC achievement, CURRICULUM
Abstract

The Individualized Education Program (IEP) should include a summary of the student's current skills and needs as well as annual goals that support their progress in the general education curriculum; however, IEPs for students with complex support needs may be missing required information. We investigated IEP goals and Present Levels of Academic Achievement and Functional Performance (PLAAFP) statements for 112 students with complex support needs in four educational placements to understand (a) similarities and differences in the literacy skills identified in IEP goals, (b) the extent to which students' IEP goals aligned with the literacy skills identified in their PLAAFPs, and (c) how this alignment differed across placements. Results revealed some students were missing literacy-focused content in their IEP, very few K–2 students had goals focused on early literacy skills, few students in Grades 3 to 6 had expressive writing goals, and IEP goals were inconsistently aligned with PLAAFP statements. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. DGN-Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055

Author

Afshar-Oromieh, A., Eiber, M., Fendler, W., Schmidt, M., Rahbar, K., Ahmadzadehfar, H., Umutlu, L., Hadaschik, B., Hakenberg, O., Fornara, P., Kurth, J., Neels, O., Wester, H.-J., Schwaiger, M., Kopka, K., Haberkorn, U., Herrmann, K., and Krause, B.

Subjects
Prostate Specific Membrane Antigen, PET/CT, Prostate Cancer, PSMA, Medizin, Radiology, Nuclear Medicine and imaging, General Medicine, Guideline, Positron Emission Tomography
Abstract

PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e.g. 68Ga-PSMA-11, 68GaPSMA-I&T, 68Ga-PSMA-617, 18F-DCFBC, 18F-DCFPyL, 18F-PSMA-1007, 18F-rhPSMA-7 and 18F-JK-PSMA-7). However, an official approval is available only for 68Ga-PSMA-11 (approved by the US FDA in 2020) and 18F-DCFPyL (approved by the US FDA in 2021). Recommendations for acquisition times vary from 1-2h p.i. It has been shown that for the majority of tumour lesions, the contrast in PSMAPET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder. PSMA-ligands are physiologically taken up in multiple normal organs. For some 18F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e.g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.

Published
2023

9. Effects of Climate Change on Management and Policy: Mitigation Options in the North American Boreal Forest

Author

Grissom, Perry, Alexander, Martin E., Cella, Brad, Cole, Frank, Kurth, J. Thomas, Malotte, Norman P., Martell, David L., Mawdsley, William, Roessler, James, Quillin, Robert, Ward, Paul C., Caldwell, M. M., editor, Heldmaier, G., editor, Lange, O. L., editor, Mooney, H. A., editor, Schulze, E.-D., editor, Sommer, U., editor, Kasischke, Eric S., editor, and Stocks, Brian J., editor

Published
2000
Full Text
View/download PDF

10. Rhenium SCT zur topischen Therapie des nicht-melanozytären Hautkrebs

Author

Heuschkel, M., additional, Tietze, J.K., additional, Kurth, J., additional, Krönert, M., additional, Ojak, G., additional, Grünwald, P., additional, Roewer, J., additional, Troitzsch, P., additional, Riedmiller-Schraven, A.L., additional, Dörschner, M., additional, Krause, B.J., additional, Emmert, S., additional, and Schwarzenböck, S., additional

Published
2022
Full Text
View/download PDF

22. Leitlinie 'PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms'

Author

Afshar Oromieh, Ali, Eiber, M., Fendler, W., Schmidt, M., Rahbar, K., Ahmadzadehfar, H., Umutlu, L., Hadaschik, B., Hakenberg, O.W., Fornara, P., Kurth, J., Neels, O., Wester, H.J., Schwaiger, M., Kopka, K., Haberkorn, U., Herrmann, K., and Krause, B.J.

Subjects
610 Medicine & health
Abstract

Das Ziel der vorliegenden Leitlinie ist es, den Arzt bei der Indikationsstellung, der standardisierten Durchführung, der Interpretation und der Dokumentation der Befunde einer Positronen-Emissions-Tomographie/Computertomographie (PET/CT) mit PSMA-Liganden bei Patienten mit Prostatakarzi-nom zu unterstützen. Es werden Empfehlungen zu Patientenselektion, Bilderfassung, Interpretati-on und Befundung ausgesprochen sowieLimitationen der PSMA-Liganden-PET/CT präsentiert. Die Leitlinie basiert auf einer Zusammenführung wissenschaftlicher Veröffentlichungen, Empfehlungen der Autoren und evidenzbasierter Daten.

Published
2019
Full Text
View/download PDF

34. City centre rough sleeping and street activity: project report

Author

McCormack, F, Massie, R, Machin, R, Vincent, P, Kurth, J, Morton, J, and Gidlow, C

Abstract

VOICES, Expert Citizens and Staffordshire University have collaborated on a research project which aims to help inform the debate locally about perceived city centre homelessness and anti-social behaviour. This is with a view to further inform the development of positive city centre solutions which recognise the needs of people who are engaged in street activity alongside those who live, work and shop in the city centre.\ud \ud This report presents and discusses the findings from stakeholders and core participants (those perceived to be homeless). It concludes with nine recommendations and a stakeholder action plan.

Published
2016

39. [18F]-florbetaben PET/CT Imaging in the Alzheimer's Disease Mouse Model APPswe/PS1dE9

Author

Stenzel, J., Rühlmann, C., Lindner, T., Polei, S., Teipel, S., Kurth, J., Rominger, A., Krause, B.J., Vollmar, B., and Kuhla, A.

Abstract

Background: Positron-emission-tomography (PET) using 18F labeled florbetaben allows noninvasive in vivo-assessment of amyloid-beta (Aβ), a pathological hallmark of Alzheimer's disease (AD). In preclinical research, [18F]-florbetaben-PET has already been used to test the amyloid-lowering potential of new drugs, both in humans and in transgenic models of cerebral amyloidosis. The aim of this study was to characterize the spatial pattern of cerebral uptake of [18F]-florbetaben in the APPswe/ PS1dE9 mouse model of AD in comparison to histologically determined number and size of cerebral Aβ plaques. Methods: Both, APPswe/PS1dE9 and wild type mice at an age of 12 months were investigated by smallanimal PET/CT after intravenous injection of [18F]-florbetaben. High-resolution magnetic resonance imaging data were used for quantification of the PET data by volume of interest analysis. The standardized uptake values (SUVs) of [18F]-florbetaben in vivo as well as post mortem cerebral Aβ plaque load in cortex, hippocampus and cerebellum were analyzed. Results: Visual inspection and SUVs revealed an increased cerebral uptake of [18F]-florbetaben in APPswe/ PS1dE9 mice compared with wild type mice especially in the cortex, the hippocampus and the cerebellum. However, SUV ratios (SUVRs) relative to cerebellum revealed only significant differences in the hippocampus between the APPswe/PS1dE9 and wild type mice but not in cortex; this differential effect may reflect the lower plaque area in the cortex than in the hippocampus as found in the histological analysis. Conclusion: The findings suggest that histopathological characteristics of Aβ plaque size and spatial distribution can be depicted in vivo using [18F]-florbetaben in the APPswe/PS1dE9 mouse model.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results